Longitudinal MR-based proton-density fat fraction (PDFF) and T2* for the assessment of associations between bone marrow changes and myelotoxic chemotherapy - Takeaways - MDSpire

Longitudinal MR-based proton-density fat fraction (PDFF) and T2* for the assessment of associations between bone marrow changes and myelotoxic chemotherapy

  • By

  • Felix G. Gassert

  • Julia Kranz

  • Florian T. Gassert

  • Benedikt J. Schwaiger

  • Christian Bogner

  • Marcus R. Makowski

  • Leander Glanz

  • Jonathan Stelter

  • Thomas Baum

  • Rickmer Braren

  • Dimitrios C. Karampinos

  • Alexandra S. Gersing

  • September 11, 2023

  • 0 min

Share

  • 1

    Myelotoxic chemotherapy reduces hematopoietic cells in bone marrow, increasing fat content and leading to osteoporosis and fracture risk.

  • 2

    MRI-based proton density fat fraction (PDFF) provides a non-invasive method to assess bone marrow fat without radiation exposure.

  • 3

    The study evaluates PDFF and T2* changes in patients undergoing myelotoxic chemotherapy compared to those receiving non-myelotoxic treatments.

  • 4

    Nineteen patients receiving myelotoxic chemotherapy were matched with control patients for a comprehensive analysis of bone marrow changes.

  • 5

    The findings aim to establish PDFF and T2* as reliable biomarkers for early detection of chemotherapy-induced bone marrow alterations.

Original Source(s)

Related Content